Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma

Link:

Celgene International Sarl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. Multiple myeloma is the second most commonly diagnosed blood cancer worldwide.

Translate into: cs pl ru de ja nl es ar pt fr el it ko tr no fi hu sv ro hi bg et lt lt sk tl iw hr id ca lv sl sr uk vi
Link: http://www.medicalnewstoday.com/articles/124564.php
Complete RSS
<<< Back

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma - témata

Cancer, Drug, REVLIMID(R), Receives, Marketing, Authorization, From, Health, Canada, For, Treatment, Multiple, Myeloma, Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment, Multiple Myeloma , International, Sarl, (NASDAQ:, CELG), REVLIMID, (lenalidomide), Celgene International Sarl (NASDAQ: CELG), REVLIMID (lenalidomide), Health Canada, Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma,

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization From Health Canada For Treatment Of Multiple Myeloma - témata

Podobné zprávy

RSS sources

Your own sources

Public sources